跳至主要内容
临床试验/NCT04787692
NCT04787692已完成不适用

Impact of Daily, Digital and Behavioral Tele-health Tapering Program for Perioperative Surgical Patients Exposed to Opioids and Benzodiazepines.

The University of Texas Health Science Center, Houston2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2020年8月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
2
主要终点
Number of patients that engage and participate in the process

研究概览

简要总结

The purpose of this study is to examine the safety, acceptability, and feasibility of a controlled taper off of opioids and/or benzodiazepines, with the use of behavioral health tele-health based therapy services, in the perioperative patient.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Preoperative benzodiazepines opioid dependence (daily use of opioids or benzodiazepines preoperatively) (Naive: No Meds 30 Days Prior to surgery,Opioid tolerant/dependant: Use of Meds on Most Days For 1 or more months prior to surgery)
  • Subject willing to use Lucid Lane program to provide behavioral health support perioperative period up to 6 months post-op for tolerant opioid/benzo users
  • Subject is willing to discuss Lucid Lane progress with the University of Texas Health Science Center(UTHealth) perioperative team and prescribing clinicians
  • Subject is willing to sign a Lucid Lane Client Agreement
  • Willing to sign an informed consent

排除标准

  • Serious mental illnesses including schizophrenia-spectrum disorders, severe bipolar disorder, and severe major depression.
  • Active suicidal ideations
  • Patients on methadone or buprenorphine for treatment of opioid use disorder (i.e. for treatment of addiction, and not for treatment of pain)
  • Patient unwilling to use or not possessing access to a device that allows for video visits (e.g. a smartphone, tablet, or computer)
  • Patients who are on palliative care
  • Insufficient ability to use English to participate in the consent process, the intervention or study assessments.
  • Insufficient ability to provide informed consent to participate
  • If the patient misses more than 2 lucid lane sessions per week, the staff will be immediately notified by Lucid Lane.

结局指标

主要结局

Number of patients that engage and participate in the process

时间窗: 180 days post intervention

Engagement and participation are defined as patient's commitment for 1 hour a week as scheduled.

次要结局

  • Emotional well-being as measured by the Generalized Anxiety Disorder 7-item (GAD-7) scale(180 days post intervention)
  • Emotional well-being as measured by the The Patient Health Questionnaire 9 (PHQ-9)(30 days post intervention)
  • Percentage of patients in the naive group that successfully taper off of the benzodiazepine or opioid(90 days post intervention)
  • Quality of life as measured by the Quality of life Score(180 days post intervention)
  • Percentage of patients in the tolerant group that successfully taper off of the benzodiazepine or opioid(180 days post intervention)
  • Symptoms as measured by the Edmonton Symptom Assessment System (ESAS)(30 days post intervention)
  • Emotional well-being as measured by the Patient Health Questionnaire 9 (PHQ-9)(180 days post intervention)
  • Well-Being as measured by the Edmonton Symptom Assessment System (ESAS)(180 days post intervention)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Evan Pivalizza

Professor

The University of Texas Health Science Center, Houston

研究点 (2)

Loading locations...

相似试验